BSE filing, NSE: SUNPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Sun Pharmaceutical Industries Ltd: key numbers
- Share price
- ₹1,777.70
- Market cap
- ₹4,26,530 Cr
- Revenue (annual)
- ₹58,462 Cr
- Net profit (annual)
- ₹11,479 Cr
- P/E (TTM)
- 35.3×Sector 45.9×
- Promoter holding
- 52.68%-1.80% QoQ
- FII holding
- 14.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sun Pharmaceutical Industries Ltd
All →Sun Pharmaceutical Industries Annual General Meeting
Sun Pharma's postal ballot passed all seven special resolutions, including ESOP 2026 approval and borrowing and security limits. No monetary transaction is stated.
Sun Pharmaceutical Industries Earnings Call Transcript: Key Takeaways
Sun Pharma delivered resilient double-digit revenue growth despite U.S. specialty headwinds, masking underlying margin pressure from lower Lenalidomide sales.
Sun Pharmaceutical Industries Other Announcement
Sun Pharma's board appointed Deloitte as Statutory Auditors under mandatory rotation, effective from the FY 2026-27 AGM. This follows SRBC & CO's second five-year term completion.
Sun Pharmaceutical Industries Q2 FY27 Results: Net Profit ₹1,995 Cr, Down 36.2% YoY
Sun Pharmaceutical Industries Ltd reported revenue from operations of ₹16,199 Cr (+11.9% YoY) and net profit of ₹1,995 Cr (-36.2% YoY) for Q2 FY27.
- Key figure
- Net profit ₹1,995 Cr · -36.2% YoY
Sun Pharmaceutical Industries Regulatory Approval
Sun Pharma gained US FDA approval for ILUMYA in adults with active psoriatic arthritis. The approval extends the drug's psoriasis use, with no financial value stated.
Sun Pharmaceutical Industries Debt & Borrowing: ₹7,816 Cr
Sun Pharma completed allotment of ₹7,816 crore NCDs via private placement, exercising its greenshoe option of ₹816 crore. The unsecured debentures carry 8.05–8.20% coupons maturing October 2031.
- Value
- ₹7,816 Cr
- Execution
- 5 years and 1 day (26 Oct 2026 to 27 Oct 2031)
Other board meeting date announcements
All →Banas Finance Board Meeting Date
Banas Finance schedules a board meeting on 5 November 2026 to approve unaudited Q2 and half-year results. Trading window stays closed until 48 hours after results declaration.
Thirumalai Chemicals Board Meeting Date
Thirumalai Chemicals has informed the exchanges that its board will meet on November 5, 2026. The meeting will consider unaudited results for the quarter and half year ended September 30, 2026.
Super Spinning Mills Board Meeting Date
Super Spinning Mills schedules its board meeting for November 5, 2026 to consider unaudited quarterly results. Trading window stays closed until 48 hours after the meeting.
Lead Reclaim and Rubber Products Board Meeting Date
Lead Reclaim will meet on 05 November 2026 to consider half-yearly unaudited results for September 2026. Trading window remains closed until 07 November 2026.
Oval Projects Engineering Board Meeting Date
Oval Projects Engineering will hold a board meeting on November 4, 2026 to consider half-year results and a warrant issue. Agenda items are proposed; no amount stated.
Novartis India Board Meeting Date
Evonile Pharma will hold a board meeting on November 4, 2026 to approve the rights issue letter of offer. BSE granted in-principle approval for the rights issue.